NORFLEX Drug Patent Profile
✉ Email this page to a colleague
When do Norflex patents expire, and when can generic versions of Norflex launch?
Norflex is a drug marketed by Pai Holdings Pharm and Bausch and is included in two NDAs.
The generic ingredient in NORFLEX is orphenadrine citrate. There are nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the orphenadrine citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Norflex
A generic version of NORFLEX was approved as orphenadrine citrate by WATSON LABS on March 15th, 1982.
Summary for NORFLEX
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 81 |
Clinical Trials: | 3 |
Patent Applications: | 869 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NORFLEX at DailyMed |
Recent Clinical Trials for NORFLEX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Illinois College of Medicine at Peoria | Phase 4 |
OSF Healthcare System | Phase 4 |
Sagent Pharmaceuticals Inc. | Phase 4 |
US Patents and Regulatory Information for NORFLEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pai Holdings Pharm | NORFLEX | orphenadrine citrate | INJECTABLE;INJECTION | 013055-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bausch | NORFLEX | orphenadrine citrate | TABLET, EXTENDED RELEASE;ORAL | 012157-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |